C3 and hyperinsulinemic hypoglycemia, familial, 4: For reducing complement activation due to FH deficiency, drug compounds targeting C3, FB, C5, FP, C3b, C3bB, and C3 convertase are predicted to be efficacious in reducing disease severity (Figure 10).